Clinical Hematology International最新文献_第3页

Clinical and Cytogenetic Characterization, and Outcome of Chronic Lymphocytic Leukemia Patients in a Single Tertiary Center in Saudi Arabia. 沙特阿拉伯单一三级中心慢性淋巴细胞白血病患者的临床和细胞遗传学特征及预后。

Clinical Hematology International Pub Date : 2023-06-01 DOI: 10.1007/s44228-023-00035-9

Areej Al Mugairi, Ekremah Alzarea, Abdulaziz Almosa, Feisal Alsomali, Abdulmajeed Alqahtani, Fawaz Alhamied, Faris Albogami, Lubna Al Zajdali, Mohammed AlBalwi, Emad Masaudi, Mohsen Alzahrani, Ayman Al Hijazi, Moussab Damlaj, Ahmed Alaskar

引用次数: 0

The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma. 多发性骨髓瘤维持试验的现状

Clinical Hematology International Pub Date : 2023-06-01 DOI: 10.1007/s44228-023-00044-8

Syed Maaz Tariq, Al-Ola Abdallah, Aaron Goodman, Douglas Sborov, Ghulam Rehman Mohyuddin, Alec Britt

引用次数: 0

Prophylactic Trimethoprim-Sulfamethoxazole for Allogeneic Hematopoietic Stem Cell Transplant Recipients During the Pre-engraftment Period. 异基因造血干细胞移植前预防使用甲氧苄啶-磺胺甲恶唑。

Clinical Hematology International Pub Date : 2023-06-01 DOI: 10.1007/s44228-023-00029-7

Kelly J Gaffney, Theresa A Urban, Mariana Lucena, Lisa Rybicki, Navneet S Majhail, Sherif Beniameen Mossad

{"title":"Prophylactic Trimethoprim-Sulfamethoxazole for Allogeneic Hematopoietic Stem Cell Transplant Recipients During the Pre-engraftment Period.","authors":"Kelly J Gaffney, Theresa A Urban, Mariana Lucena, Lisa Rybicki, Navneet S Majhail, Sherif Beniameen Mossad","doi":"10.1007/s44228-023-00029-7","DOIUrl":"https://doi.org/10.1007/s44228-023-00029-7","url":null,"abstract":"Background: Our institution has used trimethoprim-sulfamethoxazole (TMP-SMX) as the antibacterial agent of choice for infection prophylaxis during the pre-engraftment period in the allogeneic transplant (allo-HCT) population.Methods: This retrospective, single center study was developed to compare the safety of that antibacterial prophylaxis to fluoroquinolones in allo-HCT. The primary endpoint was time to neutrophil engraftment.Results: A total of 366 patients were reviewed (TMP-SMX n = 332, fluoroquinolone n = 34). No difference in days to neutrophil engraftment was found (median 15 versus 16 days, p = 0.62). Hyperkalemia was more common in the TMP-SMX cohort (32.2% versus 14.7%, p = 0.035); this did not contribute to a higher rate of agent discontinuation or arrhythmia. There was no significant difference in the incidence of neutropenic fever; however, those in the TMP-SMX cohort were more likely to have microbiologically confirmed bacteremia (24.1% versus 8.8% respectively, p = 0.043). There was no significant difference in infections. No long-term implication of prophylactic antibacterial agent selection was observed in terms of graft-versus-host-disease, underlying disease relapse, or mortality.Conclusion: The use of TMP-SMX was associated with a higher likelihood of bacteremia and hyperkalemia; however, this did not result in increased hospital stay, escalation of care, or mortality. The use of TMP-SMX for prophylaxis during the pre-engraftment period for allo-HCT recipients is safe and effective.","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9589069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Thinking Outside the Box in Mediastinal Lymphoma Management. 纵隔淋巴瘤治疗的创新思维。

Clinical Hematology International Pub Date : 2023-06-01 DOI: 10.1007/s44228-023-00045-7

Marwa Alhamss, Riad El Fakih

引用次数: 0

Thromboembolism Early After Glucocorticoid Administration in Patients with Autoimmune Hemolytic Anemia. 自身免疫性溶血性贫血患者糖皮质激素治疗后早期血栓栓塞。

Clinical Hematology International Pub Date : 2023-06-01 DOI: 10.1007/s44228-023-00043-9

Kohei Shiroshita, Mikio Okayama, Hiroki Soma, Yuki Sato, Hiroyoshi Hayashi, Yuka Shiozawa, Shinichiro Okamoto, Ken Sadahira

引用次数: 0

Refractory Anaplastic Large Cell Lymphoma Rescued by the Combination of the Second-Generation ALK Inhibitor Brigatinib, High-dose Chemotherapy and Allogeneic Stem Cell Transplantation: A Case Report and Review of the Literature. 第二代ALK抑制剂布加替尼、大剂量化疗和异体干细胞移植联合治疗难治性间变性大细胞淋巴瘤1例报告及文献复习

Clinical Hematology International Pub Date : 2023-06-01 DOI: 10.1007/s44228-023-00038-6

Giulia Caddeo, Cristina Tecchio, Matteo Chinello, Rita Balter, Ada Zaccaron, Virginia Vitale, Vincenza Pezzella, Elisa Bonetti, Marta Pillon, Elisa Carraro, Lara Mussolin, Simone Cesaro

{"title":"Refractory Anaplastic Large Cell Lymphoma Rescued by the Combination of the Second-Generation ALK Inhibitor Brigatinib, High-dose Chemotherapy and Allogeneic Stem Cell Transplantation: A Case Report and Review of the Literature.","authors":"Giulia Caddeo, Cristina Tecchio, Matteo Chinello, Rita Balter, Ada Zaccaron, Virginia Vitale, Vincenza Pezzella, Elisa Bonetti, Marta Pillon, Elisa Carraro, Lara Mussolin, Simone Cesaro","doi":"10.1007/s44228-023-00038-6","DOIUrl":"https://doi.org/10.1007/s44228-023-00038-6","url":null,"abstract":"The treatment of pediatric patients with refractory or relapsed anaplastic large cell lymphoma (ALCL) is still a major challenge. In addition to conventional chemotherapy and stem cell transplantation, new therapeutic options such as anti-CD30 drugs and anaplastic lymphoma kinase (ALK) inhibitors have been recently introduced in this setting. Among ALK inhibitors, only the first-generation molecule crizotinib is approved for pediatric use, while second-generation molecules, such as brigatinib, are still under investigation. Here we report the case of a 13-year-old boy diagnosed with stage IV ALCL, refractory to first-line conventional chemotherapy and second-line therapy with the anti CD30 antibody-drug conjugate brentuximab-vedotin, who finally achieved remission after a combination of conventional high-dose chemotherapy and the second-generation ALK inhibitor brigatinib. The latter was chosen for its ability to penetrate through the blood-brain barrier, due to the persistent involvement of the patient's cerebral nervous system. The remission was then consolidated with an allogeneic hematopoietic stem cell transplantation (HSCT) from an unrelated donor using myeloablative conditioning with total body irradiation. At 24 months after HSCT, the patient is in complete remission, alive and well. An updated review regarding the use of ALK inhibitors in ALCL patients is provided.","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9581029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

CD34 Stem Cell Boost in Pediatric Allogeneic Stem Cell Transplant Recipients: A Case Series and Review of Literature. 儿童同种异体干细胞移植受者的CD34干细胞增加:病例系列和文献综述。

Clinical Hematology International Pub Date : 2023-06-01 DOI: 10.1007/s44228-023-00042-w

Sara Bowman, Joe Stanek, Rajinder Bajwa, Veronika Polishchuk, Rolla Abu-Arja, Hemalatha G Rangarajan

{"title":"CD34 Stem Cell Boost in Pediatric Allogeneic Stem Cell Transplant Recipients: A Case Series and Review of Literature.","authors":"Sara Bowman, Joe Stanek, Rajinder Bajwa, Veronika Polishchuk, Rolla Abu-Arja, Hemalatha G Rangarajan","doi":"10.1007/s44228-023-00042-w","DOIUrl":"https://doi.org/10.1007/s44228-023-00042-w","url":null,"abstract":"Patients with poor graft function (PGF) or declining donor chimerism (DC) post allogeneic hematopoietic cell transplantation (HCT) may benefit from a CD34-selected stem cell boost (SCB). We retrospectively studied outcomes of fourteen pediatric patients (PGF: 12 and declining DC: 2), with a median age of 12.8 (range 0.08-20.6) years at HCT, who received a SCB. Primary and secondary endpoints included resolution of PGF or improvement in DC (≥ 15% increase), overall survival (OS) and transplant-related mortality (TRM), respectively. The median CD34 dose infused was 7.47 × 106/kg (range 3.51 × 106-3.39 × 107/kg). Among patients with PGF who survived ≥ 3 months post-SCB (n = 8), we observed a non-significant decrease in the cumulative median number of red cell transfusions, platelet transfusions, and GCSF but not intravenous immunoglobulin doses in the 3 months before and after SCB. Overall response rate (ORR) was 50%, with 29% complete and 21% partial responses. ORR was better in recipients who received lymphodepletion (LD) pre-SCB versus none (75% versus 40%; p = 0.56). The incidence of acute and chronic graft-versus-host-disease was 7% and 14%, respectively. The 1-year OS was 50% (95% CI 23-72%) and TRM was 29% (95% CI 8-58%). SCB was effective in half of our cohort with possible benefit of LD pre-SCB.","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9589295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety of CAR-T Cell Therapy in Patients With Renal Failure/Acute Kidney Injury: Focused Review. CAR-T细胞治疗肾衰竭/急性肾损伤患者的安全性:重点综述

Clinical Hematology International Pub Date : 2023-06-01 DOI: 10.1007/s44228-023-00037-7

Israr Khan, Nida Khan, Natalie Wolfson, Kawthar Djebabria, Mohammad Ebad Ur Rehman, Faiz Anwer

{"title":"Safety of CAR-T Cell Therapy in Patients With Renal Failure/Acute Kidney Injury: Focused Review.","authors":"Israr Khan, Nida Khan, Natalie Wolfson, Kawthar Djebabria, Mohammad Ebad Ur Rehman, Faiz Anwer","doi":"10.1007/s44228-023-00037-7","DOIUrl":"https://doi.org/10.1007/s44228-023-00037-7","url":null,"abstract":"Chimeric antigen receptor (CAR) T-cell therapy is novel immunotherapy targeting specifically cancerous cells, and has been shown to induce durable remissions in some refractory hematological malignancies. However, CAR T-cell therapy has adverse effects, such as cytokine release syndrome (CRS), immune effector-associated neurotoxicity syndrome (ICANS), tumor lysis syndrome (TLS), and acute kidney injury (AKI), among others. Not many studies have covered the repercussions of CAR T-cell therapy on the kidneys. In this review, we summarized the available evidence on the safety profile of CAR T-cell therapy in patients with pre-existing renal insufficiency/AKI and in those who develop AKI as a result of CAR T-cell therapy. With a 30% incidence of AKI post-CAR T-cell, various pathophysiological mechanisms, such as CRS, hemophagocytic lymphohistiocytosis (HLH), TLS, serum cytokines, and inflammatory biomarkers, have been shown to play a role. However, CRS is commonly reported as an underlying mechanism. Overall, 18% of patients in our included studies developed AKI after receiving CAR T-cell therapy, and most cases were reversible with appropriate therapy. While phase-1 clinical trials exclude patients with significant renal toxicity, two studies (Mamlouk et al. and Hunter et al.) reported successful treatment of dialysis-dependent patients with refractory diffuse large B-cell lymphoma, and demonstrated that CAR T-cell therapy and lymphodepletion (Flu/Cy) can be safely administered.","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241763/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9642554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH). 多发性骨髓瘤的最新进展:国际临床血液学学会(IACH)举行的国际骨髓瘤学会(IMS 2022)圆桌辩论。

Clinical Hematology International Pub Date : 2023-06-01 DOI: 10.1007/s44228-023-00036-8

Nizar J Bahlis, Luciano J Costa, Thierry Facon, Jean-Luc Harousseau, Salomon Manier, Aurore Perrot, Cyrille Touzeau, Mohamad Mohty

引用次数: 0

'Standing on the Shoulders of the Giants': Dr. Robert Kyle. “站在巨人的肩膀上”:罗伯特·凯尔博士。

Clinical Hematology International Pub Date : 2023-03-01 DOI: 10.1007/s44228-022-00021-7

Mohamad Mohty, Robert A Kyle

引用次数: 1